Performance of Chromogenic In Situ Hybridization on Testing HER2 Status in Breast Carcinomas With Chromosome 17 Polysomy and Equivocal (2+) HercepTest Results

Chromogenic In Situ Hybridization Is a Reliable Method for DetectingHER2Gene Status in Breast Cancer

(2009) Yun Gong et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations

(2009) Guido Sauter et al.   JOURNAL OF CLINICAL ONCOLOGY

Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response

(2009) Monica M Reinholz et al.   LANCET ONCOLOGY

Determination ofHER2Amplification by In Situ Hybridization

(2008) John M.S. Bartlett et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Regulation of Estrogen-Dependent Transcription by the LIM Cofactors CLIM and RLIM in Breast Cancer

(2008) S. A. Johnsen et al.   CANCER RESEARCH

HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer

(2008) M. F. Press et al.   CLINICAL CANCER RESEARCH

High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system

(2008) Allen M Gown et al.   MODERN PATHOLOGY